Leerink Partnrs Forecasts IQVIA’s FY2024 Earnings (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV) – Analysts at Leerink Partnrs boosted their FY2024 EPS estimates for IQVIA in a report released on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $10.13 per share for the year, up from their previous estimate of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

A number of other research analysts also recently commented on IQV. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Leerink Partners reissued an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Truist Financial reduced their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $257.60.

IQVIA Trading Down 0.3 %

Shares of NYSE IQV opened at $200.37 on Friday. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The business has a fifty day simple moving average of $213.40 and a 200-day simple moving average of $224.61. The company has a market cap of $36.37 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Trading of IQVIA

Hedge funds and other institutional investors have recently modified their holdings of the company. ORG Partners LLC increased its stake in IQVIA by 2,376.2% in the 2nd quarter. ORG Partners LLC now owns 520 shares of the medical research company’s stock valued at $108,000 after buying an additional 499 shares during the last quarter. Blue Trust Inc. boosted its position in IQVIA by 702.9% during the second quarter. Blue Trust Inc. now owns 281 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 246 shares during the last quarter. Gradient Investments LLC increased its position in shares of IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after purchasing an additional 6,134 shares during the last quarter. Harrell Investment Partners LLC boosted its holdings in shares of IQVIA by 2.4% in the 2nd quarter. Harrell Investment Partners LLC now owns 12,219 shares of the medical research company’s stock valued at $2,583,000 after buying an additional 286 shares during the last quarter. Finally, 1858 Wealth Management LLC acquired a new position in IQVIA during the second quarter worth $203,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.